In what researchers are calling the most significant vaccine design breakthrough since mRNA technology, scientists announced on June 5, 2026, that an AI-designed universal coronavirus vaccine has passed its first human clinical trial — proving safe, well-tolerated, and capable of generating immune responses against multiple coronaviruses simultaneously.
The vaccine was developed using artificial intelligence to design antigens that target conserved regions shared across multiple coronavirus strains. These include SARS-CoV-2 and its variants, SARS-CoV-1, MERS-CoV, and several bat coronaviruses considered potential pandemic threats.
